首页> 美国卫生研究院文献>other >Cross-Platform Assessment of Genomic Imbalance Confirms the Clinical Relevance of Genomic Complexity and Reveals Loci with Potential Pathogenic Roles in Diffuse Large B-Cell Lymphoma
【2h】

Cross-Platform Assessment of Genomic Imbalance Confirms the Clinical Relevance of Genomic Complexity and Reveals Loci with Potential Pathogenic Roles in Diffuse Large B-Cell Lymphoma

机译:跨平台的基因组失衡评估证实了基因组复杂性的临床相关性并揭示了弥漫性大型B细胞淋巴瘤中具有潜在致病作用的基因座

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genomic copy number alterations (CNAs) in diffuse large B-cell lymphoma (DLBCL) have roles in disease pathogenesis but overall clinical relevance remains unclear. Herein, an unbiased algorithm was uniformly applied across three genome profiling datasets comprising 392 newly-diagnosed DLBCL specimens that defined 32 overlapping CNAs, involving 36 minimal common regions (MCRs). Scoring criteria were established for 50 aberrations within the MCRs while considering peak gains/losses. Application of these criteria to independent datasets revealed novel candidate genes with coordinated expression, such as CNOT2, potentially with pathogenic roles. No one single aberration significantly associated with patient outcome across datasets, but genomic complexity, defined by imbalance in more than one MCR, significantly portended adverse outcome in two of three independent datasets. Thus, the standardized scoring of CNAs currently developed can be uniformly applied across platforms, affording robust validation of genomic imbalance and complexity in DLBCL and overall clinical utility as biomarkers of patient outcome.
机译:弥漫性大B细胞淋巴瘤(DLBCL)中的基因组拷贝数改变(CNA)在疾病发病机理中起作用,但总体临床相关性仍不清楚。在本文中,将无偏算法统一应用于三个基因组分析数据集,其中包括392个新诊断的DLBCL标本,这些标本定义了32个重叠的CNA,涉及36个最小公共区域(MCR)。在考虑峰值增益/损耗的同时,为MCR中的50个像差建立了评分标准。这些标准应用于独立数据集揭示了具有协调表达的新候选基因,例如CNOT2,可能具有致病作用。没有一个像差与整个数据集的患者结果显着相关,但是由多个MCR中的不平衡所定义的基因组复杂性,在三个独立的数据集中有两个显着地预示了不良结果。因此,当前开发的CNA的标准化评分可以在各个平台上统一应用,从而可以可靠地验证基因组失衡和DLBCL的复杂性,以及作为患者预后的生物标志物的整体临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号